# A Comparison of PF708 and Forteo in Osteoporosis Patients

> **NCT03002428** · PHASE3 · COMPLETED · sponsor: **Pfenex, Inc** · enrollment: 181 (actual)

## Conditions studied

- Osteoporosis

## Interventions

- **DRUG:** Teriparatide (PF708)
- **DRUG:** Teriparatide (Forteo)

## Key facts

- **NCT ID:** NCT03002428
- **Lead sponsor:** Pfenex, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12
- **Primary completion:** 2018-05
- **Final completion:** 2018-05
- **Target enrollment:** 181 (ACTUAL)
- **Last updated:** 2018-05-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03002428

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03002428, "A Comparison of PF708 and Forteo in Osteoporosis Patients". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT03002428. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*